Robert Tarran

Robert Tarran

University of North Carolina at Chapel Hill

H-index: 51

North America-United States

About Robert Tarran

Robert Tarran, With an exceptional h-index of 51 and a recent h-index of 36 (since 2020), a distinguished researcher at University of North Carolina at Chapel Hill, specializes in the field of Ion Channels. Lung infections. Cystic Fibrosis. COPD.

His recent articles reflect a diverse array of research interests and contributions to the field:

Effects of nicotine content and preferred flavor on subjective responses to e-cigarettes: a randomized, placebo-controlled laboratory study

Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society Report

The Orai1 Antagonist ELD607 Safely Reduces Lung Inflammation in G551D Cystic Fibrosis Ferrets

The Orai1 Antagonist, ELD607, Reduces Chronic Neutrophilic Inflammation in βENaC Mice

Ethanol alters e-liquid physicochemical properties, toxicity, and nicotine deposition

Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model

171 Abnormal calcium signaling in cystic fibrosis neutrophils is inversely correlated with FEV1 and can be corrected with the Orai1 antagonist ELD607

Passaging Primary Human Bronchial Epithelia Reduces CFTR-Mediated Fluid Transport and Alters mRNA Expression

Robert Tarran Information

University

Position

___

Citations(all)

13101

Citations(since 2020)

4933

Cited By

10043

hIndex(all)

51

hIndex(since 2020)

36

i10Index(all)

117

i10Index(since 2020)

98

Email

University Profile Page

University of North Carolina at Chapel Hill

Google Scholar

View Google Scholar Profile

Robert Tarran Skills & Research Interests

Ion Channels. Lung infections. Cystic Fibrosis. COPD

Top articles of Robert Tarran

Title

Journal

Author(s)

Publication Date

Effects of nicotine content and preferred flavor on subjective responses to e-cigarettes: a randomized, placebo-controlled laboratory study

Nicotine and Tobacco Research

Michael P Bremmer

Alana M Campbell

Kai Xia

Robert Tarran

Susan S Girdler

...

2024/3/1

Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society Report

Milica Vukmirovic

Kambez H Benam

Jason J Rose

Scott Turner

Chelsea M Magin

...

2024/1

The Orai1 Antagonist ELD607 Safely Reduces Lung Inflammation in G551D Cystic Fibrosis Ferrets

F Sassano

S Ahmad

J Iskarpatyoti

A Schmalstig

D Glawe

...

2024/5

The Orai1 Antagonist, ELD607, Reduces Chronic Neutrophilic Inflammation in βENaC Mice

S Ahmad

M Biggart

F Sassano

A Ghosh

R Tarran

2024/5

Ethanol alters e-liquid physicochemical properties, toxicity, and nicotine deposition

Matthew GS Biggart

J Wrennall

Michael Strenta

K Rouillard

D Hill

...

2024/5

Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model

American Journal of Respiratory and Critical Care Medicine

Saira Ahmad

Joe A Wrennall

Alexandra S Goriounova

Malika Sekhri

Jason A Iskarpatyoti

...

2024/3/15

171 Abnormal calcium signaling in cystic fibrosis neutrophils is inversely correlated with FEV1 and can be corrected with the Orai1 antagonist ELD607

Journal of Cystic Fibrosis

J Wrennall

A Ghosh

F Sassano

R Tarran

2023/10/1

Passaging Primary Human Bronchial Epithelia Reduces CFTR-Mediated Fluid Transport and Alters mRNA Expression

NUTRIENTS

Francesca Velotti

Roberta Bernini

2023/4/1

Vaping-Induced Proteolysis Causes Airway Dehydration

A Ghosh

RD Coakley

DB Hill

M Kesimer

NE Alexis

...

2023/5

18 CFTR modulators increase viral mobility in healthy and cystic fibrosis airway epithelial cells

Journal of Cystic Fibrosis

J Wykoff

K Shaffer

A Pitcairn

E Worthington

R Tarran

...

2023/10/1

Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure …

Alternatives to Laboratory Animals

Martha M Moore

Irene Abraham

Mark Ballantyne

Holger Behrsing

Xuefei Cao

...

2023/1

ELD403 as a Novel Anti-viral Therapy for RSV-related Infections in Cystic Fibrosis

R Tarran

F Sassano

M Biggart

2023/5

21 ELD403 demonstrates anti-viral activity by aggregating respiratory syncytial virus and reducing the free viral load

Journal of Cystic Fibrosis

M Biggart

F Sassano

R Tarran

2023/10/1

A Novel Co-Culture Model Reveals Enhanced CFTR Rescue in Primary Cystic Fibrosis Airway Epithelial Cultures with Persistent Pseudomonas aeruginosa Infection

Cells

Gentzsch M. Cholon DM

Greenwald MA

Higgs MG

Quinney NL

Boyles SE

...

2023

Super resolution microscopy analysis reveals increased Orai1 activity in asthma and cystic fibrosis lungs

Journal of Cystic Fibrosis

Alexandra S Goriounova

Rodney C Gilmore

Joe A Wrennall

Robert Tarran

2023/1/1

The Novel Orai1 Antagonist ELD607 Rescues the Hyperinflammatory Ca2+ Signaling Seen in CF Neutrophils

J Wrennall

A Ghosh

M Strenta

MF Sassano

R Tarran

2023/5

3 ELD607, a novel Orai1 antagonist, reduces inflammation and clears Burkholderia cepacia complex and multidrug-resistant Pseudomonas aeruginosa from the lungs

Journal of Cystic Fibrosis

S Ahmad

F Sassano

R Tarran

2023/10/1

Vaping-Induced Proteolysis Causes Airway Surface Dehydration

International Journal of Molecular Sciences

Arunava Ghosh

Raymond D Coakley

Neil E Alexis

Robert Tarran

2023/10/19

ELD607, a Novel Anti-Orai1 Peptide, Clears Methicillin-resistant Staphylococcus Aureus and Reduces Inflammation in the Lungs

S Ahmad

J Wrennall

MF Sassano

R Tarran

2023/5

Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTR

Molecular Therapy-Methods & Clinical Development

Maximillian Woodall

Robert Tarran

Rhianna Lee

Hafssa Anfishi

Stella Prins

...

2023/9/14

See List of Professors in Robert Tarran University(University of North Carolina at Chapel Hill)